Our Pricing

Can You Take Saxenda and Xenical Together? UK Guidance

Published on: June 03, 2026

Many patients ask can you take Saxenda and Xenical together UK to maximise weight loss results. While both medications are MHRA-licensed for weight management, combining them requires careful clinical assessment by a UK prescriber to ensure safety and appropriateness for your individual circumstances.

Can You Take Saxenda and Xenical Together UK: The Clinical Answer

From a pharmacological perspective, Saxenda (liraglutide) and Xenical (orlistat) work through entirely different mechanisms, which means they do not directly interact with each other [1]. Saxenda is a GLP-1 receptor agonist that reduces appetite and slows gastric emptying, while Xenical blocks approximately 30% of dietary fat absorption in the intestine [2].

However, whether you can take Saxenda and Xenical together UK depends on your individual medical history, current medications, and treatment goals. A UK prescriber must assess whether dual therapy is clinically appropriate, as combining treatments increases the overall medication burden and potential side effect profile [3].

At Cured Pharmacy, our UK-registered clinical team evaluates each combination request individually. Superintendent pharmacist Tarun Kumar (GPhC 2233073) notes that most patients achieve significant results with a single evidence-based treatment, but combination therapy may be considered in specific circumstances where monotherapy has proven insufficient.

How Saxenda and Xenical Work Differently

Understanding the distinct mechanisms helps explain why patients consider combining these treatments. Saxenda contains liraglutide, a GLP-1 receptor agonist that mimics a natural hormone your body produces after eating [1]. It works centrally in the brain to reduce appetite and increase feelings of fullness, while also slowing how quickly food leaves your stomach.

Xenical contains orlistat, which works entirely in your digestive system rather than systemically. It inhibits pancreatic and gastric lipases—enzymes responsible for breaking down dietary fats—preventing approximately 30% of fat from being absorbed [2]. The unabsorbed fat passes through your system, reducing overall calorie intake from fatty meals.

Because these mechanisms do not overlap, there is no direct pharmacological interaction. However, combining them means managing two distinct side effect profiles simultaneously, which requires careful clinical oversight.

Saxenda Mechanism and Clinical Evidence

In the SCALE clinical trial programme, patients using Saxenda achieved an average weight loss of 8-9% of initial body weight over 56 weeks when combined with diet and exercise [1]. The medication is administered as a daily subcutaneous injection, with doses gradually increased over five weeks to the maintenance dose of 3.0mg daily.

Xenical (Orlistat) Clinical Profile and Availability

Xenical is available in 120mg capsules, taken three times daily with meals containing fat. Clinical trials demonstrate an average additional weight loss of 2-3kg compared to diet and exercise alone over 12 months [2]. At Cured Pharmacy, Xenical Orlistat 120mg Capsules are available from £32.00, while generic Orlistat starts from £32.00 offering the same active ingredient at a lower cost.

The medication works best when combined with a reduced-calorie diet containing approximately 30% of calories from fat. Taking Xenical with very low-fat meals provides minimal benefit, as there is insufficient fat to block. Common side effects relate to the unabsorbed fat passing through the digestive system, including oily stools, increased bowel movements, and flatulence with discharge [2].

For patients who find the 120mg dose produces excessive gastrointestinal effects, Orlos (Orlistat) 60mg is available from £32.00. This lower-strength formulation blocks approximately 25% of dietary fat rather than 30%, often with improved tolerability whilst still providing clinically meaningful weight loss support.

Who Is Suitable for Xenical Treatment

NICE guidelines recommend orlistat for adults with a BMI of 30 kg/m² or above, or 28 kg/m² or above with associated risk factors such as type 2 diabetes or high blood pressure [4]. Treatment should only continue beyond three months if at least 5% of initial body weight has been lost since starting therapy.

Potential Benefits and Risks of Combination Therapy

The theoretical advantage of combining Saxenda and Xenical lies in addressing weight loss through two complementary pathways: appetite suppression centrally and fat absorption reduction peripherally. Some patients who have plateaued on one medication may wonder whether adding the second could overcome this stall.

However, combination therapy has not been extensively studied in large-scale clinical trials, meaning evidence for enhanced efficacy remains limited [3]. More importantly, combining treatments doubles the medication management requirements and side effect monitoring. Patients would need to manage daily Saxenda injections, three-times-daily Xenical capsules, and potentially overlapping gastrointestinal side effects.

From a practical perspective, most UK prescribers recommend optimising a single evidence-based treatment before considering combination approaches. This includes ensuring dietary modifications are fully implemented, physical activity is maximised, and any behavioural or psychological factors affecting weight are addressed through appropriate support.

When Combination Therapy Might Be Considered

A UK prescriber might consider combination therapy in specific circumstances: when a patient has achieved partial but insufficient results with Saxenda alone, when they have previously responded well to orlistat but require additional support, or when clinical factors suggest dual-mechanism therapy could be beneficial. Any such decision requires comprehensive assessment and ongoing monitoring by a registered healthcare professional.

Side Effects to Consider with Dual Treatment

Saxenda commonly causes gastrointestinal side effects including nausea, vomiting, diarrhoea, and constipation, particularly during the dose escalation phase [1]. These effects typically improve over several weeks as your body adjusts. More serious but rare risks include pancreatitis, gallbladder problems, and increased heart rate.

Xenical's side effects are predominantly gastrointestinal and directly related to its mechanism of blocking fat absorption [2]. Oily spotting, flatulence with discharge, urgent bowel movements, and fatty or oily stools are common, especially when dietary fat intake exceeds recommendations. These effects can be managed by adhering to a lower-fat diet but may be socially inconvenient for some patients.

Combining both medications means potentially experiencing side effects from both simultaneously. The overlapping gastrointestinal effects—particularly diarrhoea from Saxenda and oily stools from Xenical—could prove particularly challenging to manage. This is why careful clinical assessment and ongoing monitoring are essential if dual therapy is pursued.

Alternative Approaches to Enhanced Weight Loss

Before considering combination therapy, several evidence-based alternatives may provide enhanced results. Newer GLP-1 receptor agonists such as semaglutide (Wegovy) have demonstrated superior weight loss outcomes compared to liraglutide in head-to-head trials, with average reductions of 15-17% of body weight [5]. Tirzepatide (Mounjaro), a dual GIP/GLP-1 receptor agonist, has shown even greater efficacy with average weight reductions exceeding 20% in clinical trials [6].

For patients already using Saxenda, optimising the current treatment may prove more effective than adding Xenical. This includes ensuring the full 3.0mg maintenance dose is reached if tolerated, addressing any barriers to dietary adherence, increasing physical activity levels, and exploring behavioural support programmes. Many patients find that structured support alongside medication produces better outcomes than medication alone.

At Cured Pharmacy, our UK clinical team provides comprehensive assessment to identify the most appropriate treatment pathway for your individual circumstances. This includes reviewing your weight loss history, current medications, medical conditions, lifestyle factors, and treatment preferences to recommend the evidence-based option most likely to help you achieve sustainable results. All prescription treatments require online clinical assessment, completed in under three minutes, with genuine UK-licensed medicines dispensed discreetly to your door.

Scientific References

1. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
2. Torgerson, J. S., et al. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
3. Apovian, C. M., et al. (2019). Pharmacological management of obesity: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 100(2), 342–362. https://doi.org/10.1210/jc.2014-3415 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2014). Obesity: identification, assessment and management (Clinical guideline CG189). NICE. https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
5. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
6. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication or combining treatments.